
## 2019-nCoV drug discovery community effort 

Current worldwide research efforts against 2019-nCoV include clinical and preclinical studies, and drug candidates suggested from these studies are provided here and updated daily. We also include our initial data anlaysis results from previous antiviral drug discovery studies to facilitate such efforts. We seek experts' opinions and efforts to further validate these candidates, which will be continuously re-defined and selected based on their prior data on 2019-nCoV related viruses and newly generated data on 2019-nCoV.


### 2019-nCoV Clinical Trials registration list

A list of registered clinical trials for 2019-nCoV infection is collected in the table below. This data was initially collected from [Biocentury](https://www.biocentury.com/article/304368) and sorted based on registration date.

| Registration number                                          | Intervention                                                 | Type                      | Registration date |
| ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------- | ----------------- |
| [ChiCTR2000029308](http://www.chictr.org.cn/showprojen.aspx?proj=48684) | Lopinavir/ritonavir; interferon α 2b                         | Antiviral                 | 2020/1/23         |
| [ChiCTR2000029386](http://www.chictr.org.cn/showprojen.aspx?proj=http://www.chictr.org.cn/showprojen.aspx?proj=48777) | Lopinavir/ritonavir; methylprednisolone; interferon α        | Antiviral; Corticosteroid | 2020/1/28         |
| [ChiCTR2000029387](http://www.chictr.org.cn/showprojen.aspx?proj=48782) | Lopinavir/ritonavir; ribavirin; interferon α-1b              | Antiviral                 | 2020/1/28         |
| [NCT04244591](https://clinicaltrials.gov/ct2/show/NCT04244591) | Methylprednisolone                                           | Corticosteroid            | 2020/1/28         |
| [ChiCTR2000029468](http://www.chictr.org.cn/showprojen.aspx?proj=48919) | Lopinavir/ritonavir; emtricitabine/tenofovir alafenamide fumarate | Antiviral                 | 2020/2/2          |
| [ChiCTR2000029496](http://www.chictr.org.cn/showprojen.aspx?proj=48809) | Lopinavir/ritonavir; Novaferon                               | Antiviral                 | 2020/2/3          |
| [ChiCTR2000029539](http://www.chictr.org.cn/showprojen.aspx?proj=48991) | Lopinavir/ritonavir                                          | Antiviral                 | 2020/2/3          |
| [ChiCTR2000029541](http://www.chictr.org.cn/showprojen.aspx?proj=48992) | Darunavir/cobicistat; Lopinavir/ritonavir; thymosin          | Antiviral                 | 2020/2/3          |
| [ChiCTR2000029542](http://www.chictr.org.cn/showprojen.aspx?proj=48968) | Chloroquine                                                  | Antiviral                 | 2020/2/3          |
| [ChiCTR2000029548](http://www.chictr.org.cn/showprojen.aspx?proj=49015) | Baloxavir Marboxil; Favipiravir; Lopinavir/ritonavir                                                  | Antiviral                 | 2020/2/4          |
| [NCT04252885](https://clinicaltrials.gov/ct2/show/NCT04252885) | Umifenovir (Arbidol)                                | Antiviral                 | 2020/2/5         |
| [NCT04255017](https://clinicaltrials.gov/ct2/show/NCT04255017) | Umifenovir (Arbidol); Oseltamivir; Lopinavir/ritonavir                   | Antiviral                 | 2020/2/5         |
| [NCT04257656](https://clinicaltrials.gov/ct2/show/NCT04257656) | Remdesivir                                                   | Antiviral                 | 2020/2/6          |
| [ChiCTR200029600](http://www.chictr.org.cn/showprojen.aspx?proj=49042) | Favipiravir, Lopinavir/Ritonavir + alpha-Interferon          | Antiviral                 | 2020/2/6          |
| [ChiCTR2000029853](http://www.chictr.org.cn/showprojen.aspx?proj=49532) | Azvudine          | Antiviral                 | 2020/2/16          |
| [ChiCTR2000030000](http://www.chictr.org.cn/showprojen.aspx?proj=49748) | Ganovo (Danoprevir)/ritonavir; Peginterferon alfa-2a          | Antiviral                 | 2020/2/19          |
| [ChiCTR2000030055](http://www.chictr.org.cn/showprojen.aspx?proj=49864) | Dipyridamole | Inhibitor | 2020/2/22 |


### 2019-nCoV related projects around the world
The PDF document below published by [mybiogate](http://mybiogate.com) lists a collection of projects related to 2019-nCoV.  This table organizes the projects as: therapeutics, vaccines, diagnostic tools, and medical devices. Additionally, each project's organization, brief introduction, research or clinical progress, location, and other potential indications are listed. In total, there are 55 therapeutic, 17 vaccine, 14 diagnostic, and 16 medical device projects listed on this table.

[Download PDF](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/file_quanqiuzhongwenxiangmu.pdf)

---

## Detailed Drug information of current published or ongoing in vitro or clinical studies on 2019-nCoV

The information below is collected from recent research articles, news articles, or clinical reports of 2019-nCoV studies contributed from various research groups worldwide. The source links or full article download are provided to facilitate your own investigation and research on these molecules. 


| Drug Name          | Structure                                                    | MoA                                         | Indication                                                   | DrugBank URL                                     | Anti-2019nCoV Evidence          | Reference                                                    |
| ------------------ | ------------------------------------------------------------ | ------------------------------------------- | ------------------------------------------------------------ | ------------------------------------------------ | ------------------------------- | ------------------------------------------------------------ |
| Remdesivir         | ![img3](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_remdesivir.png) | RNA  polymerase inhibitor                   | Anti-Ebola passed Phase III, nCoV Phase III                  | [DB14761](https://www.drugbank.ca/drugs/DB14761) | In Vitro Assay, Clinical report, Clinical trial | [7](http://www.xinhuanet.com/english/2020-01/30/c_138742163.htm); [8](https://www.nejm.org/doi/10.1056/NEJMoa2001191); [14](http://clarivate.com.cn/coronavirus-resources/images/Remdesivir.pdf); [15](https://www.nature.com/articles/s41422-020-0282-0); [16](https://clinicaltrials.gov/ct2/show/NCT04257656) |
| Lopinavir          | ![img1](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_lopinavir.png) | Protease inhibitor                          | Anti-HIV approved                                            | [DB01601](https://www.drugbank.ca/drugs/DB01601) | Clinical trial                  | [1](http://www.chictr.org.cn/showprojen.aspx?proj=48684); [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919); [3](http://www.chictr.org.cn/showprojen.aspx?proj=48809); [4](http://www.chictr.org.cn/showprojen.aspx?proj=48991); [5](http://www.chictr.org.cn/showprojen.aspx?proj=48782); [6](http://www.nhc.gov.cn/yzygj/s7652m/202001/7450028ab6084101ae8110f0aaf81271.shtml) |
| Ritonavir          | ![img2](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_ritonavir.png) | Protease inhibitor                          | Anti-HIV approved                                            | [DB00503](https://www.drugbank.ca/drugs/DB00503) | Clinical trial                  | [1](http://www.chictr.org.cn/showprojen.aspx?proj=48684); [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919); [3](http://www.chictr.org.cn/showprojen.aspx?proj=48809); [4](http://www.chictr.org.cn/showprojen.aspx?proj=48991); [5](http://www.nhc.gov.cn/yzygj/s7652m/202001/7450028ab6084101ae8110f0aaf81271.shtml); [6](http://www.chictr.org.cn/showprojen.aspx?proj=48782) |
| Emtricitabine      | ![img13](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_emtricitabine.png) | nucleoside reverse  transcriptase inhibitor | Anti-HIV  approved, anti-HBV                                 | [DB00879](https://www.drugbank.ca/drugs/DB00879) | Clinical trial                  | [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919)     |
| Tenofovir          | ![img14](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_tenofovir.png) | nucleoside reverse  transcriptase inhibitor | Anti-HIV Phase III, anti-HBV                                 | [DB14126](https://www.drugbank.ca/drugs/DB14126) | Clinical trial                  | [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919)     |
| Ribavirin          | ![img12](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_ribavirin.png) | viral mRNA and  protein synthesis inhibitor | Anti-HCV,  Anti-HBV, Anti-SARS, Anti-influenza, etc          | [DB00811](https://www.drugbank.ca/drugs/DB00811) | Clinical trial                  | [5](http://www.chictr.org.cn/showprojen.aspx?proj=48782)     |
| Umifenovir         | ![img5](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_arbidol.png) |                                             | Influenza approved, nCoV Phase 4                             | [DB13609](https://www.drugbank.ca/drugs/DB13609) | Clinical trial                  | [9](https://clinicaltrials.gov/ct2/show/NCT04252885); [22](https://clinicaltrials.gov/ct2/show/NCT04255017)        |
| Favipiravir        | ![img6](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_favipiravir.png) | RNA polymerase inhibitor                    | Anti-influenza approved, anti-Ebola Phase II                 | [DB12466](https://www.drugbank.ca/drugs/DB12466) | Clinical trial                  | [10](http://www.xinhuanet.com/english/2020-02/01/c_138747115.htm); [18](http://www.chictr.org.cn/showprojen.aspx?proj=49042) |
| Darunavir          | ![img10](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_darunavir.png) | Protease inhibitor                          | Anti-HIV approved                                            | [DB01264](https://www.drugbank.ca/drugs/DB01264) | Clinical trial                  | [11](http://www.chictr.org.cn/showprojen.aspx?proj=48992)    |
| Cobicistat         | ![img11](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_cobicistat.png) |                                             | Anti-HIV approved                                            | [DB09065](https://www.drugbank.ca/drugs/DB09065) | Clinical trial                  | [11](http://www.chictr.org.cn/showprojen.aspx?proj=48992)    |
| Methylprednisolone | ![img9](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_methylprednisolone.png) | Corticosteroid                              | nCoV Phase II, allergic asthma and rheumatic disorders approved | [DB00959](https://www.drugbank.ca/drugs/DB00959) | Clinical trial                  | [12](http://www.chictr.org.cn/showprojen.aspx?proj=48777); [13](https://clinicaltrials.gov/ct2/show/NCT04244591) |
| Baloxavir marboxil  | ![img14](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_baloxavirmarboxil.png) |  Polymerase inhibitor  | anti-influenza approved | [DB13997](https://www.drugbank.ca/drugs/DB13997) | Clinical trial  | [21](http://www.chictr.org.cn/showprojen.aspx?proj=49015) |
| Oseltamivir        | ![img15](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_oseltamivir.png) |  Neuraminidase inhibitor; Sialidase inhibitor       | anti-influenza approved, nCoV Phase III | [DB00198](https://www.drugbank.ca/drugs/DB00198) | Clinical trial  | [22](https://clinicaltrials.gov/ct2/show/NCT04255017) |
| IFN alpha-1b       |                                                              | Immunomodulation                            | Interferon                                                   |                                                  | Clinical trial                  | [5](http://www.chictr.org.cn/showproj.aspx?proj=48782); [6](http://www.nhc.gov.cn/yzygj/s7652m/202001/7450028ab6084101ae8110f0aaf81271.shtml) |
| Danoprevir       |  ![img17](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_danoprevir.png)            | Protease inhibitor                            | anti-HCV Phase III, nCoV Phase 4           |     [DB11779](https://www.drugbank.ca/drugs/DB11779)        | Clinical trial                  | [23](http://www.chictr.org.cn/showprojen.aspx?proj=49748) |
| Peginterferon alfa-2a       |                                                              | Immunomodulation                            | HCV approved, nCoV Phase 4                                                  |       [DB00008](https://www.drugbank.ca/drugs/DB00008)      | Clinical trial                  | [23](http://www.chictr.org.cn/showprojen.aspx?proj=49748) |
| Chloroquine        | ![img4](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_chloroquine.png) |                                             | Antimalarial approved, anti-HIV phase III, anti-HCV, nCoV Phase  4 | [DB14761](https://www.drugbank.ca/drugs/DB14761) | In Vitro Assay, Clinical trial  | [7](http://www.xinhuanet.com/english/2020-01/30/c_138742163.htm); [15](https://www.nature.com/articles/s41422-020-0282-0); [17](http://www.chictr.org.cn/showprojen.aspx?proj=48968) |
| Azvudine        | ![img4](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_azuvudine.png) |                                             | anti-HIV approved | [PubChem 24769759](https://pubchem.ncbi.nlm.nih.gov/compound/Azvudine) | Clinical trial  | [19](http://www.chictr.org.cn/showproj.aspx?proj=49532); [20](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140803/) |
| Dipyridamole | ![img20](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_dipyridamole.png) | Adenosine deaminase and phosphodiesterase inhibitor | nCoV Phase 4; Phase 4 completed for stroke prevention; Phase 4 completed for coronary arteriosclerosis | [DB00975](https://www.drugbank.ca/drugs/DB00975) | Clinical Trial | [24](http://www.chictr.org.cn/showprojen.aspx?proj=49864); [25](https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1.full.pdf) |

---

## Data analysis results from previous coronavirus related drug discovery records

A collection of drug candidates with previously published positive SARS/MERS experimental results.

|  Drug name  | DrugBank ID  | Mechanism of action  | Experimental activity  | Methods  | Measurement  | Value | Unit  |
| ---- | --- | --- | --- | --- | --- | --- | --- |
|  Remdesivir  | [DB14761](https://www.drugbank.ca/drugs/DB14761)  | Nucleobindin-1 (NUCB1) Inhibitors  | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Viral replication assay  | IC-50  | 1.00E-08  | M  |
|  Emetine  | [DB13393](https://www.drugbank.ca/drugs/DB13393)  | Platelet-Derived Growth Factor (PDGF) Inhibitors;Signal Transduction Modulators;Angiogenesis Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 1.50E-07  | M  |
|  Nafamostat mesilate  | [DB12598](https://www.drugbank.ca/drugs/DB12598)  | Tryptase Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Vero cells (TMPRSS2-expressing) transfected with MERS  | IC-50  | 1.00E-09  | M  |
|  Alisporivir  | [DB12139](https://www.drugbank.ca/drugs/DB12139)  | P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Cyclophilin Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | RNA assay  | IC-50  | 8.00E-07  | M  |
|  Niclosamide  | [DB06803](https://www.drugbank.ca/drugs/DB06803)  | Cytochrome P450 CYP1A2 Inhibitors;Quorum Sensing (Pseudomonas aeruginosa) Inhibitors;Neuropeptide Y4 (NPY Y4) Receptor Positive Allosteric Modulators;Autophagy Inducers;Wnt Signaling Inhibitors  | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 1.00E-07  | M  |
|  Rupintrivir  | [DB05102](https://www.drugbank.ca/drugs/DB05102)  | HRV 3C Protease Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Viral replication assay  | IC-50  | 3.00E-07  | M  |
|  Geldanamycin  | [DB02424](https://www.drugbank.ca/drugs/DB02424)  | Signal Transduction Modulators;Heat Shock Protein 90 (Hsp90) Inhibitors  | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  |   | IC-50  | 9.10E-07  | M  |
|  Sinefungin  | [DB01910](https://www.drugbank.ca/drugs/DB01910)  | Coactivator Associated Arginine Methyltransferase 1 (CARM1; PRMT4) Inhibitors;Histone-Lysine N-Methyltransferase SETD7 (SET7/9) Inhibitors;Protein-L-Isoaspartate(D-Aspartate) O-Methyltransferase (PCMT1; PIMT) Inhibitors;Epigenetic Modifier Modulators  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  |   | IC-50  | 3.83E-07  | M  |
|  Mycophenolic acid sodium salt  | [DB01024](https://www.drugbank.ca/drugs/DB01024)  | Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 1.70E-07  | M  |
|  Mycophenolate mofetil  | [DB00688](https://www.drugbank.ca/drugs/DB00688)  | Hydroxycarboxylic Acid Receptor 2 (HCAR2; NIACR1; GPR109A) Agonists;Signal Transduction Modulators;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Viral replication assay  | IC-50  | 2.30E-07  | M  |
|  Chloroquine  | [DB00608](https://www.drugbank.ca/drugs/DB00608)  |   | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  |   | IC-50  | 8.00E-10  | M  |
|  Gemcitabine hydrochloride  | [DB00441](https://www.drugbank.ca/drugs/DB00441)  | Ribonucleoside-Diphosphate Reductase Inhibitors;Pyrimidine Antagonists  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 4.40E-07  | M  |
|  Promazine  | [DB00420](https://www.drugbank.ca/drugs/DB00420)  | Signal Transduction Modulators;Dopamine Receptor Antagonists  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Cytopathicity assay  | MIC  | 1.00E-07  | M  |
|  Azithromycin  | [DB00207](https://www.drugbank.ca/drugs/DB00207)  | Nonsense Mutation Suppressors;50S Ribosomal Protein Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Luciferine/luciferase assay  | IC-50  | 1.00E-07  | M  |
|  cyclosporin  | [DB00091](https://www.drugbank.ca/drugs/DB00091)  | Cyclophilin Inhibitors;Mitochondrial Permeability Transition (MPT) Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | RNA assay  | IC-50  | 8.00E-07  | M  |

## Data analysis results from previous other antiviral drug discovery records

A collection of drug candidates in pipelines or marketed for different antiviral indications. All candidates have at least completed Phase I studies. However, not all have in vitro anti-coronavirus or anti-2019nCoV evidence yet, further studies using 2019-nCoV specific assays are required to evaluate their anti-2019nCoV potential. 


### 1. Antiviral candidates selected from viral replication assay

| Drug name               | DrugBank ID                                      | Clinical Information                                         | Mechanism of action                                          | Experimental activity                                        | Method                  | parameter | PX          | mean        | unit |
| ----------------------- | ------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------------------------ | ----------------------- | --------- | ----------- | ----------- | ---- |
| Deferiprone             | [DB08826](https://www.drugbank.ca/drugs/DB08826) | 1. Phase 4 completed  for acute iron intoxication <br/>2. Phase 4 completed for Hepatic impairment <br/>3.  Phase 4 completed for impaired kidney function <br/>4. Phase 4 completed for  Beta-Thalassemia <br/>5. Phase 4 completed for hemosiderosis <br/>6. Phase 4  completed for Prolonged QT Interval <br/>7. Phase III completed for Parkinson's  disease; <br/>Marketed for iron toxicity | Chelating Agents;Cytochrome P450 CYP4F2 Inhibitors           | Infection, BK polyomavirus remission/reduction, IN VITRO     | Viral replication assay | IC-50     | 8.46 | 3.50E-09    | M    |
| Raltegravir potassium   | [DB06817](https://www.drugbank.ca/drugs/DB06817) | Phase 4 completed  for HIV <br/>Marketed for Anti-Retroviral HIV | HIV Integrase Inhibitors                                     | Infection, xenotropic murine leukemia virus-related virus remission/reduction, IN VITRO | Viral replication assay | IC-50     | 8.30 | 0.000000005 | M    |
| Verdinexor              | [DB12207](https://www.drugbank.ca/drugs/DB12207) | Phase 1 completed  for basic science on health volunteers    | Exportin-1 (CRM1, XPO1) Receptor Antagonists;Signal Transduction Modulators | Infection, JC polyomavirus remission/reduction, IN VITRO     | Viral replication assay | IC-50     | 8.12 | 7.50E-09    | M    |
| Brincidofovir           | [DB12151](https://www.drugbank.ca/drugs/DB12151) | Phase 3 completed  for adenovirus infections                 | DNA Polymerase Inhibitors                                    | Infection, JC polyomavirus remission/reduction, IN VITRO     | Viral replication assay | IC-50     | 7.7 | 0.00000002  | M    |
| Remdesivir              | [DB14761](https://www.drugbank.ca/drugs/DB14761) | 1. Phase III for  Ebola <br>2. Phase III for nCoV           | Nucleobindin-1 (NUCB1) Inhibitors                            | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO | Viral replication assay | IC-50     | 7.60 | 0.000000025 | M    |
| Verdinexor              | [DB12207](https://www.drugbank.ca/drugs/DB12207) | Phase I completed  for basic science experiments on healthy volunteers | Exportin-1 (CRM1, XPO1) Receptor Antagonists;Signal Transduction Modulators | Infection, adenovirus remission/reduction, IN VITRO          | Viral replication assay | IC-50     | 7.52 | 0.00000003  | M    |
| Cidofovir               | [DB00369](https://www.drugbank.ca/drugs/DB00369) | Phase 4 completed  for cytomegalovirus <br/>Marketed for CMV in AIDS patients | DNA Polymerase Inhibitors                                    | Infection, cytomegalovirus remission/reduction, IN VITRO     | Viral replication assay | IC-99     | 7.22  | 0.00000006  | M    |
| Alvocidib hydrochloride | [DB03496](https://www.drugbank.ca/drugs/DB03496) | 1. Phase II  completed for sarcomas <br>2. Phase II completed for renal cancers; <br>3. Phase II  completed for melanoma <br>4. Phase II completed for other cancers including:  myeloma, carcinoma, esophageal, endometrial, leukaemia, etc. | Cyclin-Dependent Kinase 1 (CDK1) Inhibitors;Signal Transduction Modulators;Cyclin-Dependent Kinase 6 (CDK6) Inhibitors;CDK9/Cyclin T1 Inhibitors;Baculoviral IAP Repeat-Containing Protein 5 (BIRC5; Survivin) Inhibitors;Apoptosis Inducers;Cyclin-Dependent Kinase 7 (CDK7) Inhibitors;Cyclin-Dependent Kinase 2 (CDK2) Inhibitors;Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Inhibitors;Cyclin-Dependent Kinase 4 (CDK4) Inhibitors;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors;Apoptosis Regulator Bcl-2 Inhibitors | Infection, herpes virus remission/reduction, IN VITRO        | Viral replication assay | IC-50     | 7.00 | 1.00E-07    | M    |
| Ganciclovir             | [DB01004](https://www.drugbank.ca/drugs/DB01004) | 1. Phase 4 active  for viral pneumonia <br>2. Phase 4 completed for DNA virus infections <br>3. Phase 4  completed for CMV <br>4. Phase 4 completed for viral sepsis | DNA Polymerase Inhibitors                                    | Infection, herpes simplex virus remission/reduction, IN VITRO | Viral replication assay | IC-50     | 7           | 0.0000001   | M    |

### 2. Antiviral candidates selected from different in vitro assays

| Drug_name     | DrugBank  ID                                     | Clinical Information                                         | Mechanism of action                                          | Experimental activity                                        | Method                                                       | parameter | PX          | mean     | unit |
| ------------- | ------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------------------------ | --------- | ----------- | -------- | ---- |
| Presatovir    | [DB12165](https://www.drugbank.ca/drugs/DB12165) | Phase II completed  for Respiratory Syncytial Virus          | Respiratory Syncytial Virus (RSV) Fusion Inhibitors;Viral Fusion Inhibitors | Infection, respiratory syncytial virus (RSV) remission/reduction, IN VITRO | Cytopathicity assay                                          | IC-50     | 11.74 | 1.80E-12 | M    |
| Brincidofovir | [DB12151](https://www.drugbank.ca/drugs/DB12151) | Phase III completed  for AdV, BKV, CMV, EBV, and HHV6        | DNA Polymerase Inhibitors                                    | Infection, cytomegalovirus remission/reduction, IN VITRO     | DNA assay                                                    | IC-50     | 11.70    | 2.00E-12 | M    |
| Sorivudine    | [DB11998](https://www.drugbank.ca/drugs/DB11998) | Phase III  completed for Chickenpox, HIV                     | DNA Polymerase Inhibitors                                    | Infection, varicella zoster virus remission/reduction, IN VITRO | Plaque assay                                                 | IC-50     | 10.62 | 2.40E-11 | M    |
| Peramivir     | [DB06614](https://www.drugbank.ca/drugs/DB06614) | Phase 4 completed  for influenza <br/>Marketed for influenza | Neuraminidase (Sialidase) (Influenza Virus) Inhibitors       | Neuraminidase (nonspecified subtype) (Influenza A virus) inhibition, IN VITRO | 4-Methylumbelliferyl-N-acetyl-alpha-D-neuraminic acid as substrate | Ki        | 10.85 | 1.40E-11 | M    |
| Peramivir     | [DB06614](https://www.drugbank.ca/drugs/DB06614) | Phase 4 completed  for influenza <br/>Marketed for influenza | Neuraminidase (Sialidase) (Influenza Virus) Inhibitors       | Neuraminidase (nonspecified subtype) (Influenza A virus) inhibition, IN VITRO | 4-Methylumbelliferyl-N-acetyl-alpha-D-neuraminic acid as substrate | IC-50     | 10.30    | 5.00E-11 | M    |
| Zanamivir     | [DB00558](https://www.drugbank.ca/drugs/DB00558) | Phase 4 completed  for influenza <br/>Marketed for influenza | Neuraminidase (Sialidase) (Influenza Virus) Inhibitors       | Neuraminidase (nonspecified subtype) (Influenza A virus) inhibition, IN VITRO | Chemiluminescent assay                                       | IC-50     | 10.52 | 3.00E-11 | M    |
| Sirolimus     | [DB00877](https://www.drugbank.ca/drugs/DB00877) | 1. Phase 4 completed  for renal diseases, renal failure <br>2. Phase 4 completed for kidney and heart  transplatation <br/>Marketed for kidney transplantation | CCR5 Expression Inhibitors;Cytochrome P450 CYP2D6 Inhibitors;Signal Transduction Modulators;Cytochrome P450 CYP2C9 Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Proteasome Inhibitors;Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;Drugs Targeting B-Lymphocyte Antigen CD19 | Infection, cytomegalovirus remission/reduction, IN VITRO     | Chemiluminescent assay                                       | IC-50     | 10.40 | 4.00E-11 | M    |
| Laninamivir   | [DB12791](https://www.drugbank.ca/drugs/DB12791) | Phase I completed  for influenza                             | Neuraminidase (Sialidase) (Influenza Virus) Inhibitors       | Neuraminidase (nonspecified subtype) (Influenza A virus) inhibition, IN VITRO | Fluorescent assay                                            | IC-50     | 9.96 | 1.10E-10 | M    |
| Ribavirin     | [DB00811](https://www.drugbank.ca/drugs/DB00811) | 1. nCoV clinical  trial <br>2. Phase 4 completed for HCV <br>3. Phase 3 completed for HBV <br/>Marketed for RSV, HCV, | Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Equilibrative Nucleoside Transporter ENT1 Inhibitors | Infection, respiratory syncytial virus (RSV) remission/reduction, IN VITRO | ELISA assay                                                  | IC-50     | 9.90 | 1.26E-10 | M    |

---


### 3. Top antiviral candidates with RDRP inhibition MOA selected from different assays

|  ﻿Drug name  | DrugBank ID  | Mechanism of action  | Experimental activity  | Measurement  |  Value  | Unit  | 
| ---- | --- | --- | --- | --- | --- | --- | 
|  Beclabuvir  | [DB12225](https://www.drugbank.ca/drugs/DB12225)  | RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors  | Hepatitis C (HCV) remission/reduction, IN VITRO  | IC-50  | 3.00E-09  | M  | 
|  Remdesivir    | [DB14761](https://www.drugbank.ca/drugs/DB14761)  | RNA-Dependent RNA Polymerase Inhibitor    | Ebola virus disease remission/reduction, IN VITRO    | IC-50    | 1.00E-08  | M  | 
|  Valopicitabine  | [DB13920](https://www.drugbank.ca/drugs/DB13920)  | RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors  | Hepatitis C (HCV) remission/reduction, IN VITRO  | IC-50  | 9.00E-08  | M  | 
|  Mericitabine  | [DB12045](https://www.drugbank.ca/drugs/DB12045)  | RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors  | Hepatitis C (HCV) remission/reduction, IN VITRO  | IC-50  | 1.30E-07  | M  | 
|  Lumicitabine  | [DB14808](https://www.drugbank.ca/drugs/DB14808)  | RNA-Dependent RNA Polymerase (Respiratory Syncytial Virus) Inhibitors  | Infection, respiratory syncytial virus (RSV) remission/reduction, IN VITRO  | IC-50  | 2.60E-07  | M  | 
|  Sofosbuvir  | [DB08934](https://www.drugbank.ca/drugs/DB08934)  | RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors  | Infection, dengue virus remission/reduction, IN VITRO  | IC-90  | 4.00E-07  | M  | 
|  Adafosbuvir  | [DB14906](https://www.drugbank.ca/drugs/DB14906)  | RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors  | Infection, dengue virus remission/reduction, IN VITRO  | IC-50  | 1.10E-06  | M  | 



*Compounds selected based on top PX scores from respective assays.



<br>

<br>

<br>

Your [**feedback**](https://github.com/GHDDI-AILab/Targeting2019-nCoV/issues) is highly appreciated.
